Stock Analysis of Zymeworks Inc. Common Stock (ZYME) - Birds Eye View

1W   2W   1M   3M   1Y   2Y   5Y   
Overview
Code ZYME
Close 8.48
Change 0.050 / 0.593 %
Volume 793516
Vol Change 519404 / 189.49 %
IndustryBiotechnology
SectorHealthcare
AIO Strength Index
Technical StrengthBearish
Growth Index No Significant Growth
Value Index Very Low Value Stock
Profitability Index Poor Profitability Stock
Stability Index Mild Stability


Fundamental View of Zymeworks Inc. Common Stock
PE (TTM)

-5202.96

Very Poor
Price / Book

1757.09

Very Poor
Price / Sales

2967731

Very Poor
Piotroski F Score

4.0

Indecisive
Market Cap

599577 K

Enterprise Value

-152696.42 M

ROA (TTM)

-25.76

Very Poor
ROE (TTM)

-33.85

Very Poor
Net Margin (TTM)

-57039.25

Very Poor
Revenue

11.90 %

461579 K
Net Profit

65.06 %

205239 K
Debt to Equity

0.0092

Excellent
Altman Z Score

-1.63

Very Poor
Quick Ratio

7.41

Excellent
Cash Ratio

6.71

Excellent


Highs/Lows of Zymeworks Inc. Common Stock
PeriodOld priceStock ReturnS&P 500 ReturnsHighLowHigh DateLow Date
One Week8.72 2.75 % 0.513 % 8.888.3128-May-2431-May-24
Two Week9.12 7.02 % 0.486 % 9.338.3122-May-2431-May-24
One Month8.58 1.17 % 4.80 % 9.61978.3114-May-2431-May-24
Three Month12.01 29.39 % 3.56 % 12.677.9704-Mar-2426-Apr-24
Six Months8.87 4.40 % 15.54 % 13.147.9727-Feb-2426-Apr-24
One year8.23 3.04 % 26.26 % 13.146.01527-Feb-2404-Oct-23
Two year6.72 26.19 % 27.72 % 13.144.8627-Feb-2413-Oct-22
Five year19.01 55.39 % 91.77 % 13.144.1127-Feb-2407-Sep-22


Technical View of Zymeworks Inc. Common Stock
RSI

39.31

Neutral
MACD

-0.176

Mild Bearish
ADX

17.49

Bearish
Super Trend

7.85

Mild Bullish
Williams %R

-87.02

Mild Bullish
CCI

-161.37

Mild Bullish


EMA 5

8.57

Mild Bearish
EMA 15

8.77

Strong Bearish
EMA 50

9.24

Strong Bearish
EMA 100

9.48

Strong Bearish
SMA 100

10.18

Strong Bearish
SMA 200

9.00

Whipsaw
SMA 5 / 20

8.56 / 8.94

Bearish
SMA 15 / 50

8.88 / 9.15

Mild Bearish
SMA 50 / 200

9.15 / 9.00

Mild Bullish




Charts of Zymeworks Inc. Common Stock


Returns of Zymeworks Inc. Common Stock with Peers
Period / StockZYMEHLVXSRDXSNDL
1 Week-2.75%-5.82%22.34%0%
1 Mth-1.17%-8.03%63.72%-10.12%
3 Mth-29.39%-33.11%31.85%64.44%
6mth-4.40%-11.45%28.15%55.24%
1 Year3.04%-28.67%129.46%56.34%
2 Year26.19%22.87%7.21%-43.41%
5 Years-55.39%-3.70%-
charts-
View All Together in Chart      Inline           Tile

Compare Fundamentals of Zymeworks Inc. Common Stock with Peers
Ratio / StockZYMEHLVXSRDXSNDL
PE-5202.96-828.4814.81-4.16
P/B1757.09469.975.110.448
ROA-25.76-44.4822.19-9.07
ROE-33.85-56.7334.52-10.92
Debt To Equity0.00920.1070.2520.0252
Revenue461579 K
11.90 % 		0
% 		132584 K
32.65 % 		900961 K
26.50 %
Net Income205239 K
65.06 % 		-107794.00 K
32.55 % 		6510.00 K
123.87 % 		-215673.00 K
35.64 %


Technicals of Zymeworks Inc. Common Stock with Peers
Technical / StockZYMEHLVXSRDXSNDL-
ADX17.4918.7147.9529.76
CMF-0.085-0.0319-0.419-0.287
MFI40.7236.4062.9954.02
RSI39.3137.0181.7048.18
MACD Abv SignalFalseFalseTrueFalse
Price Above 50 MAFalseFalseTrueTrue-
Price Above 200 MAFalseFalseTrueTrue-


About : Zymeworks Inc. Common Stock

Address : 108 Patriot Drive, Middletown, DE, United States, 19709
Tel : (302) 274-8744
URL : https://www.zymeworks.com
Code : ZYME, ISIN : CA98985W1023, Exchange : NASDAQ, Country : USA
Fiscal Year End : December
IPO date : 28_Apr_2017
Employee Count : 275

Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a human epidermal growth factor receptor 2 (HER2) that is in Phase 1, Phase 2, and Phase 3 clinical trials, including certain ongoing pivotal clinical trials; and zanidatamab zovodotin, a HER2 -targeted antibody-drug conjugate that is in Phase 2 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors. It also develops a pipeline of preclinical product candidates and discovery-stage programs in oncology, including immuno-oncology agents and other therapeutic areas. Zymeworks Inc. has strategic partnerships and collaborations with BeiGene, Ltd.; Celgene Corporation; Celgene Alpine Investment Co. LLC; GlaxoSmithKline Intellectual Property Development Limited; Daiichi Sankyo Co., Ltd.; Janssen Biotech, Inc.; LEO Pharma A/S; Iconic Therapeutics, Inc.; Merck Sharp & Dohme Research GmbH; and Atreca, Inc. Zymeworks Inc. was incorporated in 2003 and is based in Middletown, Delaware.


Note : All Data Generated at the End of Trading Hours (EOD Data)